| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 05/23/2002 | CA2763223A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | CA2632696A1 Modified clostridial neurotoxins with altered biological persistence |
| 05/23/2002 | CA2448729A1 Piperazinyl and piperidyl substituted heterocyclic compounds |
| 05/23/2002 | CA2429897A1 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | CA2429894A1 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | CA2429437A1 Imidazole derivatives, process for their preparation and their use |
| 05/23/2002 | CA2429329A1 Bombesin receptor antagonists |
| 05/23/2002 | CA2429195A1 Immunoglobulin superfamily proteins |
| 05/23/2002 | CA2429067A1 Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts |
| 05/23/2002 | CA2428787A1 Benzimidazole derivatives |
| 05/23/2002 | CA2428754A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | CA2428647A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | CA2428527A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | CA2428136A1 Modified clostridial neurotoxins with altered biological persistence |
| 05/23/2002 | CA2427900A1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| 05/23/2002 | CA2426089A1 Bombesin receptor antagonists |
| 05/22/2002 | EP1206573A1 26 human secreted proteins |
| 05/22/2002 | EP1206553A2 Isomerase proteins |
| 05/22/2002 | EP1206491A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 05/22/2002 | EP1206473A1 Isomeric fused pyrrolocarbazoles and isoindolones |
| 05/22/2002 | EP1206467A1 N-heterocyclic derivatives as nos inhibitors |
| 05/22/2002 | EP1206455A1 ALPHAvBETA3 INTEGRIN INHIBITORS |
| 05/22/2002 | EP1206262A1 Npy antagonists: spiroisoquinolinone derivatives |
| 05/22/2002 | EP1206233A2 Serine proteases |
| 05/22/2002 | EP1152776B1 Biodegradable, injectable oligomer-polymer composition |
| 05/22/2002 | EP0894093B1 Soluble tachykinin antagonists, the preparation and use thereof |
| 05/22/2002 | EP0563238B1 Imidazolyl-alkenoic acids |
| 05/22/2002 | CN1350537A Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 05/22/2002 | CN1350533A New ECE inhibitors, their production and their use |
| 05/22/2002 | CN1350523A Indoline derivatives as progesterohe antagonists |
| 05/22/2002 | CN1349966A Extraction and purification process of general rhubarb anthraquinone and its application in preparing kidney hypofuction-treating medicine |
| 05/22/2002 | CN1349820A Application of shinyleaf yellowhorn fruit shell in preparing cerbral function improving food and medicine |
| 05/22/2002 | CN1349810A Kidney strengthening regenerating bolus |
| 05/22/2002 | CN1349796A Pyrrole derivatives and medicine composition |
| 05/22/2002 | CN1085208C Process for preparing eprosartan |
| 05/22/2002 | CN1085097C Medicine for treating prostatic hyperplasia |
| 05/21/2002 | US6392045 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors |
| 05/21/2002 | US6392039 Coupling; salt formation |
| 05/21/2002 | US6391920 Administering hormone inhibitor; stimulant of testosterone |
| 05/21/2002 | US6391908 Oxime amide indole type sPLA2 inhibitors |
| 05/21/2002 | US6391907 Anticancer agents; contraceptives |
| 05/21/2002 | US6391904 Bone disorders |
| 05/21/2002 | US6391893 Anticancer agents |
| 05/21/2002 | US6391892 Naphthyl pharmaceutical compounds |
| 05/21/2002 | US6391887 3,4-Dihydroquinoline derivatives as nitrogen monoxide synthase (NOS) inhibitors |
| 05/21/2002 | US6391878 Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer |
| 05/21/2002 | US6391543 Screening sample for preferential nucleotide sequences; incubate sample with nucleotide sequences, monitor sample for signal indicating bound nucleotide sequences |
| 05/21/2002 | CA2268327C 3-carboxamide derivatives of 5h-pyrrolo[2,1-c][1,4]-benzodiazepines |
| 05/16/2002 | WO2002038607A2 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | WO2002038563A2 Condensed pyrazindione derivatives as pde inhibitors |
| 05/16/2002 | WO2002038561A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 05/16/2002 | WO2002038548A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 05/16/2002 | WO2002038547A1 Quinoline derivatives as nk-3 and nk-2 antagonists |
| 05/16/2002 | WO2002038186A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | WO2002038160A1 Method for the treatment of inflammation |
| 05/16/2002 | WO2002038133A2 Compositions containing hydrolytically unstable compounds |
| 05/16/2002 | WO2002038129A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | WO2002020488A3 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 05/16/2002 | WO2002017892A3 Water-dispersible encapsulated sterols |
| 05/16/2002 | WO2001098291A3 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 05/16/2002 | WO2001098290A3 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/16/2002 | WO2001089514A3 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent |
| 05/16/2002 | WO2001083547A3 Anti-inflammatory compounds and uses thereof |
| 05/16/2002 | WO2001081622A8 Diagnosis of diseases associated with dna repair |
| 05/16/2002 | WO2001072292A3 Vitamin d compounds used to stabilize kidney transplants |
| 05/16/2002 | WO2001070663A3 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 05/16/2002 | WO2001068144A3 Biodegradable immunomodulatory formulations and methods for use thereof |
| 05/16/2002 | WO2001049654A3 Substituted aminomethyl-phenyl-cyclohexane derivatives |
| 05/16/2002 | WO2001047928A3 Imidazo 1,3,5 triazinones and the use thereof |
| 05/16/2002 | WO2001045663A3 USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARs-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION |
| 05/16/2002 | WO2001032685A8 Gene expression directed by a super-psa promoter |
| 05/16/2002 | US20020058813 Spiro-indolines as Y5 receptor antagonists |
| 05/16/2002 | US20020058700 Ion channel modulating agents |
| 05/16/2002 | US20020058692 Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| 05/16/2002 | US20020058687 For therapy and prohylaxis of inflammatory diseases including joint inflammation, Crohn's disease, and inflammatory bowel disease; respiratory diseases such as chronic obstructive pulmonary disease (COPD) including asthma, chronic bronchitis |
| 05/16/2002 | US20020058681 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 05/16/2002 | US20020058631 Dipeptide derivatives |
| 05/16/2002 | US20020058630 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 05/16/2002 | US20020058616 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide) |
| 05/16/2002 | US20020058062 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism |
| 05/16/2002 | US20020058058 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 05/16/2002 | US20020058035 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 05/16/2002 | US20020058029 Anti-CD40L, anti-B7.1 (CD80), anti-B7.2(CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. |
| 05/16/2002 | DE10054641A1 Verwendung einer Zubereitung von Cimicifuga racemosa Use of a preparation of Cimicifuga racemosa |
| 05/16/2002 | CA2428179A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | CA2428164A1 Method for the treatment of inflammation |
| 05/16/2002 | CA2428159A1 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | CA2426037A1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | CA2425594A1 Compositions containing hydrolytically unstable compounds |
| 05/15/2002 | EP1205489A1 Polypeptide and nucleic acids encoding the same |
| 05/15/2002 | EP1205186A1 Compositions for promoting passive elongation of vesical smooth muscle |
| 05/15/2002 | EP1205181A2 Composition and method for parenteral administration of ibuprofen D, L-or L-Lysine salt |
| 05/15/2002 | EP1204748A2 New g-protein coupled receptor and dna sequences thereof |
| 05/15/2002 | EP1204655A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204652A1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 05/15/2002 | EP1204649A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 05/15/2002 | EP1204646A1 1,4,5,6 -tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 05/15/2002 | EP1204626A1 Ether compounds, compositions, and uses thereof |
| 05/15/2002 | EP1204414A2 Use of morphinan derivates as medicines |
| 05/15/2002 | EP0805813B1 Tricyclic vasopressin antagonists |